ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Combined Effects of Eleutherine bulbosa Ethanol Extract and Tamoxifen On Cox-2 Levels in a BaLB/c Mouse Breast Cancer Model.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChronic inflammation and oxidative stress play important roles in breast cancer progression. Cyclooxygenase-2 (COX-2) is a major proinflammatory enzyme that is often overexpressed in tumor cells. Eleutherine bulbosa (Dayak onion) is a traditional Indonesian medicinal plant with antioxidant and anti-inflammatory properties. This study aimed to evaluate the effect of a combination of ethanol extract of E. bulbosa and tamoxifen on COX-2 levels in a 7,12-dimethylbenz[a]anthracene (DMBA)-induced BALB/c mouse model.
methodsA total of thirty-six 8-10-week-old female BALB/c mice were randomly divided into six groups: a negative control, a positive control (DMBA alone), and four treatment groups that received E. bulbosa extract (180 mg/kg BW), tamoxifen (10 mg/kg BW), or their combination for 14 days. COX-2 levels were measured using an enzyme-linked immunosorbent assay (ELISA). Statistical analysis included the Shapiro-Wilk test (normality), Levene's test (homogeneity), Brown-Forsythe test, and Games-Howell post hoc test.
resultAll treatment groups showed a decrease in COX-2 levels compared to the positive control. The combination group (tamoxifen + E. bulbosa) exhibited the lowest COX-2 levels (3.86 ng/mL), close to the value observed in the negative control group (3.07 ng/mL), indicating a synergistic effect between the two agents.
conclusionThe combination of tamoxifen and E. bulbosa ethanol extract significantly reduced COX-2 levels in DMBA-induced breast cancer models. These results suggest the potential of this combination as an effective adjuvant therapy. Further studies are needed to confirm the underlying molecular mechanisms and to evaluate its toxicity profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.